Leerink Partners Maintains Buy Rating on ANI Pharmaceuticals with $100 Price Target

Leerink Partners maintains a Buy rating on ANI Pharmaceuticals with a $100 price target. The analyst consensus is Strong Buy with a $91 price target, representing a 1.11% upside from current levels. Corporate insider sentiment is negative with 66 insiders selling shares over the past quarter.

ANI Pharmaceuticals (ANIP) has been the subject of favorable analyst sentiment, with Leerink Partners maintaining a Buy rating and a $100 price target. The analyst consensus is a Strong Buy, with an average price target of $91.00, representing a 1.11% upside from current levels [1].

The positive outlook is bolstered by the company's strong earnings and sales performance. ANIP beat its earnings estimate 100% of the time in the past 12 months and its sales estimates 100% of the time as well. The next quarter's earnings estimate is $1.66, with a range of $1.46 to $1.76, and sales forecast is $206.31M, with a range of $194.73M to $215.34M [2].

However, corporate insider sentiment is negative, with 66 insiders selling shares over the past quarter. This discrepancy between analyst sentiment and insider activity may warrant further investigation. Nevertheless, the analyst consensus and historical performance suggest that ANIP could be a promising investment for investors seeking growth in the healthcare sector.

References:

[1] TipRanks - ANIP Analyst Ratings [https://www.tipranks.com/stocks/anip/forecast](https://www.tipranks.com/stocks/anip/forecast)
[2] TipRanks - ANIP Financial Forecast [https://www.tipranks.com/stocks/anip/financials](https://www.tipranks.com/stocks/anip/financials)